Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells

Bookmark and Share
Published: 27 Nov 2020
Views: 230
Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom

Dr Rachel Ambler speaks to ecancer about her presentation at the ENA virtual meeting this year.

She discussed mutations in the KRAS gene, notable in pancreatic, lung, and colorectal cancers.

Dr Ambler's research aims to find new treatments and combinations to treat these cancers with KRAS mutations. Recently, using an immune response has seemed promising, which is Dr Ambler's current research.

She explores some of the options in this realm of treatment, specifically the use of DNGR-1 expressing cells to stimulate a T-cell response - studies are promising and ongoing.